Homepage
Author:
Theriva Biologics, Inc.
Posted Date:
May 7, 2026
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
Theriva Biologics, Inc.
May 7, 2026
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
Theriva Biologics, Inc.
April 17, 2026
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Theriva Biologics, Inc.
March 23, 2026
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Theriva Biologics, Inc.
March 12, 2026
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Theriva Biologics, Inc.
February 18, 2026
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Theriva Biologics, Inc.
February 3, 2026
